Literature DB >> 17471522

Heat denaturation of fibrinogen to develop a biomedical matrix.

Gerard Marx1, Xiaode Mou, Anna Hotovely-Salomon, Lilia Levdansky, Elena Gaberman, Dimitry Belenky, Raphael Gorodetsky.   

Abstract

Native and heat denatured fibrinogen are the basis for various matrices used to establish hemostasis as well as for constructing biomedical devices. For example, fibrin microbeads (FMB) prepared by a heated ( approximately 70 degrees C) oil emulsion process were reported to be attractive to mesenchymal-type cells, such as fibroblasts, endothelial and smooth muscle cells, and useful for isolating mesenchymal stem cells from bone marrow. Here, we examined the solution properties of fibrinogen subjected to heat (47-60 degrees C). Fibrinogen exhibited maximal stability of pH(max stab) = 6.8. At physiologically relevant concentrations, Ca(II) stabilized and Zn(II) destabilized fibrinogen against heat denaturation. Scanning electron micrographs (SEM) of precipitated, heat denatured, fibrinogen showed globular structures ( approximately 400 nm diameter), composed of aggregates of >3000 fibrinogen monomers. Monoclonal antibodies (MAb) to various regions of fibrinogen, as well as two polyclonal antibody (Ab) to haptotactic peptides (Haptides) equivalent to or near the C-termini of beta and gamma-chains (beta(463-483) and gamma(372-391/411)), were used to monitor epitopic changes of fibrinogen bound to and heated on plastic ELISA plates. The pattern of altered Ab binding indicated that fibrinogen heat denaturation on plastic exposed the C-terminal epitope gamma(397-411) as well as Haptide epitopes (beta(463-483) and gamma(372-391)). Immuno-staining of FMB prepared by a heated (below 75 degrees C) oil emulsion process, also presented many exposed Haptide epitopes, which probably helped to attract cells. Our results indicated that moderately heat-denatured fibrinogen, in the form of FMB, could be used for cell culturing and biomedical applications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17471522     DOI: 10.1002/jbm.b.30842

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  7 in total

1.  Fibrinogen, riboflavin, and UVA to immobilize a corneal flap--molecular mechanisms.

Authors:  Stacy L Littlechild; Yuntao Zhang; John M Tomich; Gary W Conrad
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-06       Impact factor: 4.799

2.  Fast-degradable microbeads encapsulating human umbilical cord stem cells in alginate for muscle tissue engineering.

Authors:  Jun Liu; Hongzhi Zhou; Michael D Weir; Hockin H K Xu; Qianming Chen; Carroll Ann Trotman
Journal:  Tissue Eng Part A       Date:  2012-07-19       Impact factor: 3.845

3.  A novel "salting-out" procedure for the isolation of tumor-derived exosomes.

Authors:  Zachary Brownlee; Kristi D Lynn; Philip E Thorpe; Alan J Schroit
Journal:  J Immunol Methods       Date:  2014-04-13       Impact factor: 2.303

4.  The presence of heat-labile factors interfering with binding analysis of fibrinogen with ferritin in horse plasma.

Authors:  Kazuma Takahashi; Takashi Kondo; Yasunaga Yoshikawa; Kiyotaka Watanabe; Koichi Orino
Journal:  Acta Vet Scand       Date:  2013-09-22       Impact factor: 1.695

5.  Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles.

Authors:  Claudia Fredolini; Sanna Byström; Laura Sanchez-Rivera; Marina Ioannou; Davide Tamburro; Fredrik Pontén; Rui M Branca; Peter Nilsson; Janne Lehtiö; Jochen M Schwenk
Journal:  Sci Rep       Date:  2019-06-06       Impact factor: 4.379

6.  Biocompatible and biodegradable fibrinogen microspheres for tumor-targeted doxorubicin delivery.

Authors:  Jae Yeon Joo; Gil Yong Park; Seong Soo A An
Journal:  Int J Nanomedicine       Date:  2015-09-01

Review 7.  A review of fibrin and fibrin composites for bone tissue engineering.

Authors:  Alireza Noori; Seyed Jamal Ashrafi; Roza Vaez-Ghaemi; Ashraf Hatamian-Zaremi; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2017-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.